These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35219004)

  • 81. A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study.
    Gu R; Jia W; Zeng Y; Rao N; Hu Y; Li S; Wu J; Jin L; Chen L; Long M; Chen K; Chen L; Xiao Q; Wu M; Song E; Su F
    BMC Cancer; 2012 May; 12():161. PubMed ID: 22548922
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The combined pN stage and breast cancer subtypes in breast cancer: a better discriminator of outcome can be used to refine the 8th AJCC staging manual.
    Yang ZJ; Yu Y; Chi JR; Guan M; Zhao Y; Cao XC
    Breast Cancer; 2018 May; 25(3):315-324. PubMed ID: 29353447
    [TBL] [Abstract][Full Text] [Related]  

  • 84. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
    Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
    Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer.
    Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
    Breast Cancer; 2017 Nov; 24(6):748-755. PubMed ID: 28425014
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Impact of prognostic nutritional index on long-term outcomes in patients with breast cancer.
    Mohri T; Mohri Y; Shigemori T; Takeuchi K; Itoh Y; Kato T
    World J Surg Oncol; 2016 Jun; 14(1):170. PubMed ID: 27349744
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB
    J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Clinicopathologic and prognostic significance of serum levels of cytokines in patients with advanced serous ovarian cancer prior to surgery].
    Zhu X; Ying LS; Xu SH; Zhu CH; Xie JB
    Zhonghua Bing Li Xue Za Zhi; 2010 Oct; 39(10):666-70. PubMed ID: 21176531
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer.
    Mihály Z; Kormos M; Lánczky A; Dank M; Budczies J; Szász MA; Győrffy B
    Breast Cancer Res Treat; 2013 Jul; 140(2):219-32. PubMed ID: 23836010
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis.
    Willner J; Kiricuta IC; Kölbl O
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(4):853-63. PubMed ID: 9128962
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Nodal Ratio as a Prognostic Factor in Patients with Four or More Positive Axillary Nodes Treated with Breast-conserving Therapy and Regional Nodal Irradiation.
    Iatì G; Pontoriero A; Mondello S; Santacaterina A; Platania A; Frosina P; Raso MM; Aiello D; Arcudi A; Arena G; Marino G; Mazzei M; Rifatto C; Risoleti E; Runco R; Sansotta G; Delia P; Sindoni A; Pergolizzi S
    Anticancer Res; 2016 Jul; 36(7):3549-54. PubMed ID: 27354622
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Predictive factors on outcomes in metaplastic breast cancer.
    Leyrer CM; Berriochoa CA; Agrawal S; Donaldson A; Calhoun BC; Shah C; Stewart R; Moore HCF; Tendulkar RD
    Breast Cancer Res Treat; 2017 Oct; 165(3):499-504. PubMed ID: 28689362
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.
    Jerevall PL; Ma XJ; Li H; Salunga R; Kesty NC; Erlander MG; Sgroi DC; Holmlund B; Skoog L; Fornander T; Nordenskjöld B; Stål O
    Br J Cancer; 2011 May; 104(11):1762-9. PubMed ID: 21559019
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
    Sparano JA; Gray RJ; Ravdin PM; Makower DF; Pritchard KI; Albain KS; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Paik S; Wood WC; Keane MM; Gomez Moreno HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW
    N Engl J Med; 2019 Jun; 380(25):2395-2405. PubMed ID: 31157962
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
    Pagani O; Francis PA; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Di Leo A; Coates AS; Goldhirsch A; Gelber RD; Regan MM;
    J Clin Oncol; 2020 Apr; 38(12):1293-1303. PubMed ID: 31618131
    [TBL] [Abstract][Full Text] [Related]  

  • 96. MMP-1 expression has an independent prognostic value in breast cancer.
    Boström P; Söderström M; Vahlberg T; Söderström KO; Roberts PJ; Carpén O; Hirsimäki P
    BMC Cancer; 2011 Aug; 11():348. PubMed ID: 21835023
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Oncolytic alphavirus replicons mediated recruitment and activation of T cells.
    Bhatt DK; Meuleman SL; Hoogeboom BN; Daemen T
    iScience; 2024 Mar; 27(3):109253. PubMed ID: 38425844
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Notch, SUMOylation, and ESR-Mediated Signalling Are the Main Molecular Pathways Showing Significantly Different Epimutation Scores between Expressing or Not Oestrogen Receptor Breast Cancer in Three Public EWAS Datasets.
    Corsaro L; Gentilini D; Calzari L; Gambino VS
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627137
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Mining TCGA Database for Genes with Prognostic Value in Breast Cancer.
    Filippi A; Mocanu MM
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675137
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Identifying Associations between DCE-MRI Radiomic Features and Expression Heterogeneity of Hallmark Pathways in Breast Cancer: A Multi-Center Radiogenomic Study.
    Ming W; Zhu Y; Li F; Bai Y; Gu W; Liu Y; Sun X; Liu X; Liu H
    Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.